



HARVARD
T.H. CHAN

SCHOOL OF PUBLIC HEALTH
Powerful ideas for a healthier world

The Full Vaccine Value Assessment for Group A Streptococcus Vaccines

David E. Bloom

Harvard T.H. Chan School of Public Health

Global Vaccine and Immunization Research Forum

March 29, 2023



**World Health
Organization**



SAVAC
Strep A Vaccine Global Consortium

Mission: “to ensure that safe, effective and affordable Strep A vaccines are available and implemented to decrease the burden of Strep A disease in the most in need.”

Agenda

- Background and theoretical basis
- Comprehensive valuation framework
- Implications for Strep A vaccination

Comprehensive valuation framework

		Distribution			
Vaccination benefits		Individual	Family/ household	Society (health sector)	Society (general)
Health benefits	Direct health effects <ul style="list-style-type: none"> Reduced morbidity & mortality due to target pathogen Adverse effects of vaccination (negative benefit) 	✓			
	Prevention of secondary individual (physical) health effects <ul style="list-style-type: none"> Off-target pathogens Aggravation of comorbidities Nosocomial infections Microbiome disruption 	✓			
	Mitigation of secondary population-level health effects <ul style="list-style-type: none"> Disease transmission Antimicrobial resistance Healthcare congestion 			✓	✓
Economic benefits	Improved mental health	✓	✓		
	Reduced healthcare costs	✓	✓	✓	
	Reduced caregiving costs	✓	✓	✓	
	Reduced transportation costs	✓	✓		
	Increased labor force participation, hours worked, and income	✓	✓		✓
	Increase in productive non-market activities				
	Improved educational attainment, school attendance, and cognition	✓			✓
	Fiscal impact <ul style="list-style-type: none"> Increased tax receipts Reduced public health spending 			✓	✓
	Increased wealth/savings	✓	✓		
	Reduced risk and severity of impoverishment	✓	✓		✓
Reduced risk of economically disruptive outbreaks			✓	✓	
Social benefits	Improved social equity				✓
	Intergenerational benefits		✓		
	General risk reduction	✓	✓	✓	✓
	Improved quality of life	✓	✓		✓
	Reduced stigma	✓	✓	✓	✓

		Distribution			
Vaccination benefits		Individual	Family/ household	Society (health sector)	Society (general)
Health benefits	Direct health effects <ul style="list-style-type: none"> Reduced morbidity & mortality due to target pathogen Adverse effects of vaccination (negative benefit) 	✓			
	Prevention of secondary individual (physical) health effects <ul style="list-style-type: none"> Off-target pathogens Aggravation of comorbidities Nosocomial infections Microbiome disruption 	✓			
	Mitigation of secondary population-level health effects <ul style="list-style-type: none"> Disease transmission Antimicrobial resistance Healthcare congestion 			✓	✓
	Improved mental health	✓	✓		

		Distribution			
Vaccination benefits		Individual	Family/ household	Society (health sector)	Society (general)
Economic benefits	Reduced healthcare costs	✓	✓	✓	
	Reduced caregiving costs	✓	✓	✓	
	Reduced transportation costs	✓	✓		
	Increased labor force participation, hours worked, and income	✓	✓		✓
	Increase in productive non-market activities				✓
	Improved educational attainment, school attendance, and cognition	✓			✓
	Fiscal impact				
	<ul style="list-style-type: none"> Increased tax receipts Reduced public health spending 			✓	✓
	Increased wealth/savings	✓	✓		
	Reduced risk and severity of impoverishment	✓	✓		✓
	Reduced risk of economically disruptive outbreaks			✓	✓

		Distribution			
Vaccination benefits		Individual	Family/ household	Society (health sector)	Society (general)
Social benefits	Improved social equity				✓
	Intergenerational benefits		✓		
	General risk reduction	✓	✓	✓	✓
	Improved quality of life	✓	✓		✓
	Reduced stigma	✓	✓	✓	✓

Comprehensive valuation framework

		Distribution			
Vaccination benefits		Individual	Family/ household	Society (health sector)	Society (general)
Health benefits	Direct health effects <ul style="list-style-type: none"> Reduced morbidity & mortality due to target pathogen Adverse effects of vaccination (negative benefit) 	✓			
	Prevention of secondary individual (physical) health effects <ul style="list-style-type: none"> Off-target pathogens Aggravation of comorbidities Nosocomial infections Microbiome disruption 	✓			
	Mitigation of secondary population-level health effects <ul style="list-style-type: none"> Disease transmission Antimicrobial resistance Healthcare congestion 			✓	✓
Economic benefits	Improved mental health	✓	✓		
	Reduced healthcare costs	✓	✓	✓	
	Reduced caregiving costs	✓	✓	✓	
	Reduced transportation costs	✓	✓		
	Increased labor force participation, hours worked, and income	✓	✓		✓
	Increase in productive non-market activities				
	Improved educational attainment, school attendance, and cognition	✓			✓
	Fiscal impact <ul style="list-style-type: none"> Increased tax receipts Reduced public health spending 			✓	✓
	Increased wealth/savings	✓	✓		
	Reduced risk and severity of impoverishment	✓	✓		✓
Reduced risk of economically disruptive outbreaks			✓	✓	
Social benefits	Improved social equity				✓
	Intergenerational benefits		✓		
	General risk reduction	✓	✓	✓	✓
	Improved quality of life	✓	✓		✓
	Reduced stigma	✓	✓	✓	✓

Overarching conclusions

- Strep A vaccination would plausibly:
 - Prevent billions of cases of superficial illness and millions of deaths over several decades
 - Be cost-effective at all income levels assuming total costs in line with other new vaccines
 - Produce a wide range of health, economic, and social benefits, including potentially significant AMR mitigation
 - Yield trillions of dollars in global societal benefits
 - Generate full societal returns many times reasonable investment into their development

Thank you!
dbloom@hsph.harvard.edu